Why a top market strategist says his base case is still a 25% stock drop and a recession in 2025
Peter Berezin of BCA Research maintains a bearish outlook despite a tariff pause.
Berezin predicts a 60% chance of recession, with the S&P 500 dropping to 4,500.
Economic concerns include trade uncertainty, rising delinquencies, and a weakening labor market.
At a time when strategists across Wall Street are dialing back their recession probabilities, Peter Berezin of BCA Research is doubling down.
President Donald Trump's 90-day tariff pause was enough to ease the worries of some investors, but the chief global strategist at BCA has maintained his bearish outlook.
While Berezin has lowered his recession outlook from Liberation Day levels, he still expects an economic slowdown to unfold this year.
"I've brought down my recession probability from 75% to 60%, so it's not an overwhelming likelihood of recession, but it is still my base case. And in that base case, I would expect the S&P to trade down to around 4,500," Berezin told Business Insider. That would mark a 25% decline for the benchmark index from levels on Friday.
While 4,500 sounds like a steep drop from the near-record highs the stock market is trading out now, Berezin doesn't think it'll take much to trigger the fall.
A plunge to that level would require the S&P 500 to trade at 18 times earnings with EPS of $250. The index is currently trading at around 23 times earnings with EPS of around $260 — not too far off, in Berezin's opinion.
"At this point, it's hard to make a case to be very optimistic on either the stock market or economy," Berezin said.
The economy was already showing signs of weakness prior to the trade war fallout, Berezin said.
Back in December of 2024, Berezin was calling for a recession in 2025 coupled with a stock market plunge of over 20%. His S&P 500 target of 4,452 was one of the lowest on Wall Street.
Today, Berezin is concerned about continued trade uncertainty, a growing deficit, and a weakening consumer.
Job openings have been on a downward trend since early 2022, "removing a lot of insulation that had protected the labor market," Berezin said.
Indeed, other economists agree that the labor market might be weaker than it seems — Sam Tombs of Pantheon Macroeconomics is concerned with slowing hiring and declining small business sentiment.
Berezin also points out that consumer delinquency rates on credit cards and auto loans have been rising. In the first quarter of 2025, credit card delinquencies hit 3.05%. That's the highest level since 2011, "a year in which the unemployment rate was 8%," Berezin said.
Furthermore, as student loan collections restart after a five-year hiatus amid the pandemic, consumers' credit scores are taking an even bigger hit.
The housing market has also been a pressure point in the economy since COVID, with home affordability and inventory challenges mounting for buyers.
Berezin pointed to falling construction in May—housing starts dropped 9.8% in the month— as another sign of a slowdown.
The effective tariff rate is hovering around 15%, which is still a level that Berezin considers dangerous.
"There's probably no ideal for a tariff rate, but there are numbers that are more punitive for the economy than others," he said.
If Trump doesn't solidify trade deals soon, the economy could be in store for some major pain as businesses start to pass along price increases to consumers.
A tariff rate lower than 10% would be less disruptive to the economy, but Berezin isn't hopeful that Trump will lower his policies to that level.
"Since tariffs on China probably will be higher than tariffs in other countries, that means Trump would have to roll back his 10% base tariff that he's applied to almost all countries," Berezin said. "I don't see him doing that unless the market forces him to do it."
In fact, Berezin thinks Trump might even increase tariffs on some industries such as pharmaceuticals, semiconductors, and lumber.
Berezin doesn't see an easy way around an impending recession.
Some strategists might be hoping for Trump's Big Beautiful Bill to boost the economy through tax cuts, but unfunded tax cuts could push bond yields higher and cancel out any any stimulus.
According to the Congressional Budget Office, while the tax bill would increase GDP growth by 0.5% on average over the next 10 years, it would also push up 10-year Treasury yields by 14 basis points and increase the deficit by $2.8 trillion.
A stock market crash and economic downturn could actually be the turning point for Trump to reverse course on his policies, Berezin said. The S&P 500 dipping below 5,000 and the 10-year Treasury yield spiking above 4.5% probably influenced Trump to paus tariffs for 90 days, Berezin added.
"We could get more tariff relief, but the market has to force that. I don't think it's going to come from any other source," he said.
Read the original article on Business Insider
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
10 minutes ago
- Bloomberg
Ether Leads Crypto Selloff as US Attacks Nuclear Sites in Iran
Ether fell sharply while Bitcoin held steady after President Donald Trump said American bombers and missiles had struck Iran's three main nuclear sites. The second-ranked token fell as much as 7.7% on Sunday morning in Asia to about $2,200, its lowest intra-day level since May 9. Bitcoin briefly dipped below $101,000 but pared losses to trade relatively evenly in the aftermath of the attacks.
Yahoo
11 minutes ago
- Yahoo
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a 'Buy' rating and a $72 price target. The research firm remains bullish about the company's prospects owing to the strong potential of its drug candidates. A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The company's partnership with Takeda on Rusfertide to treat polycythemia Vera (PV) and oral IL-23 (icotrokinra) is one of the developments that underscore the research firm's favorable rating. Rusfertide demonstrated strong potential in PV patients in phase 3 trials, affirming its potential to address unmet needs. Citi is especially bullish about adding Rusfertide to existing therapies to expand its use case. In addition, the firm echoed the company's strategic partnership with Johnson & Johnson for multiple inflammation indications. According to Citi, Protagonist Therapeutics shares have outperformed over the past three months, going up by a 40% gain compared to a 2% gain of the S&P 500. It expects the company's combined revenues to climb to $700 million by 2032, above consensus estimates of $680 million. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company that develops peptide-based drugs to treat various diseases, including rare and prevalent ones. Its pipeline includes treatments for blood disorders like polycythemia Vera and inflammatory conditions like ulcerative colitis and psoriasis. While we acknowledge the potential of PTGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Wall Street Journal
28 minutes ago
- Wall Street Journal
The Tax Bill Would Deliver a Big Win for Private Schools—and Investors
Republicans' tax-and-spending megabill would give the school-choice movement a major, long-sought victory—and deliver an unusually generous tax break to wealthy taxpayers. The bill includes a new way for taxpayers—whether they are parents or not—to direct tax dollars to private-school scholarships instead of the Treasury. There is an extra twist: It could deliver virtually risk-free profits to some savvy investors.